Rol actual de la quimioterapia en cáncer de urotelio tras fracaso a platinos

Variables Selected in Baseline and Multivariate Analysis for Predictors of

Death Prior to 3 Months

Multivariates

•

Post-hoc, exploratory multivariate analysis suggested that

nivolumab-treated patients with poorer prognostic features and/or

aggressive disease when

combined

with lower or no tumor PD-L1 expression may be at higher risk of death within the

first 3 months

–

These included the following known prognostic factors: <3 months since last treatment, PD as best response to prior

treatment, and ECOG PS = 1